TheraCoat is a clinical stage specialty pharmaceutical company providing NON SURGICAL, TOPICAL solutions to address unmet needs in the field of uro-oncology.
The company is developing proprietary sustained release, hydrogel-based, drug formulations in order to redefine the role of chemotherapy for the local treatment of various forms of urinary tract cancers.
TheraCoat sustained release formulation enables longer exposure of the urinary tract tissue to the drug, as compared to standard intravesical instillations, currently administered for the treatment of urinary tract diseases.
TheraCoat core technology is based on using a proprietary and patented reverse thermal-gelation hydrogels, the TCGel family, having ideal properties for the delivery and retention of medications in the urinary tract.
The company’s lead product is MitoGel™ (sustained release formulation of the chemotherapy agent Mitomycin C) for the management of Upper Tract Urothelial Carcinoma (UTUC), an indication with high clinical unmet needs. Recently, TheraCoat was granted Orphan Drug Designation from the US FDA for MitoGel™ and will shortly commence a phase III clinical study.
In addition, TheraCoat is developing sustained release formulations of Mitomycin C for intravesical treatments for non-muscle-invasive or superficial bladder cancer (NMIBC), and botulinum toxin A formulations for interstitial cystitis (IC) and overactive bladder (OAB). These treatments together address millions of patients worldwide.
MEET US AT:
TheraCoat will exhibit its novel topical solutions in the field of urology at booth #433 . Companies and physicians interested in collaborating are welcomed to meet us.